Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.

Abstract: Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising an opioid (A), a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

Abstract: The invention relates to an intravenous pharmaceutical form of administration including undissolved active ingredient parts, and to a kit containing the constituents for producing one such form of administration.

Abstract: The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

Abstract: The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.

Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain or other conditions.

Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.

Abstract: The invention relates to crystals from optionally substituted 2-(2-pyridinyl)methylthio-1H-benzimidazole hydrates and to a method for the production thereof.

Abstract: The present invention relates to substituted propiolic acid amides, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments.

Abstract: The present invention relates to the use of a hormone combination of ethinyl oestradiol or oestradiol as oestrogen component and at least one metabolite of chlormadinone acetate selected from the group consisting of 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxychlormadinone acetate), 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxychlormadinone acetate), 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one and 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one, optionally mixed with chlormadinone acetate as gestagen component for producing a medicament at least for alleviating menstrual cycle-dependent mood swings and optionally for hormonal contraception in women.

Abstract: The invention relates to crystals from optionally substituted 2-(2-pyridinyl)methylthio-1H-benzimidazole hydrates and to a method for the production thereof.

Abstract: The present invention relates to substituted thiazoles, to methods for their production, to drugs containing these compounds and to the use of said compounds for producing drugs.

Abstract: The present invention relates to substituted propiolic acid amides, methods for the production thereof, medicaments containing these compounds and the use thereof for producing medicaments.

Abstract: The invention relates to crystals from optionally substituted 2-(2-pyridinyl)methylthio-1H-benzimidazole hydrates and to a method for the production thereof.

Abstract: The invention relates to a method for producing Grignard compounds, according to which magnesium is reacted in a suitable fluid reaction medium in a protective atmosphere with hologen-substituted organic compounds by means of microwave radiation.

Abstract: Substituted indoles of the formula I, a process for the production of such compounds, pharmaceutical preparations containing these compounds and the use of these compounds for alleviating pain.